ICOSLG and colorectal carcinoma: M2-type macrophages, Tregs, and the ICOS/ICOSL signaling pathway could become new potential targets for immune therapy in CRC, holding significant clinical value for the diagnosis, treatment, and prognosis of CRC patients.